Sunbelt Securities Inc. grew its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 22.6% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,150 shares of the biopharmaceutical company’s stock after purchasing an additional 1,317 shares during the period. Sunbelt Securities Inc. owned approximately 547.05% of Gilead Sciences worth $579,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in GILD. AQR Capital Management LLC raised its holdings in shares of Gilead Sciences by 25.7% during the 1st quarter. AQR Capital Management LLC now owns 5,213,046 shares of the biopharmaceutical company’s stock valued at $354,070,000 after buying an additional 1,066,172 shares during the period. Sterneck Capital Management LLC raised its holdings in shares of Gilead Sciences by 75.4% during the 1st quarter. Sterneck Capital Management LLC now owns 66,932 shares of the biopharmaceutical company’s stock valued at $4,546,000 after buying an additional 28,767 shares during the period. Shelton Capital Management raised its holdings in shares of Gilead Sciences by 49.8% during the 1st quarter. Shelton Capital Management now owns 206,700 shares of the biopharmaceutical company’s stock valued at $14,039,000 after buying an additional 68,731 shares during the period. Endurant Capital Management LP purchased a new stake in shares of Gilead Sciences during the 1st quarter valued at about $1,494,000. Finally, Westover Capital Advisors LLC raised its holdings in shares of Gilead Sciences by 0.8% during the 1st quarter. Westover Capital Advisors LLC now owns 5,563 shares of the biopharmaceutical company’s stock valued at $378,000 after buying an additional 46 shares during the period. 75.94% of the stock is currently owned by institutional investors and hedge funds.
In other news, EVP Gregg H. Alton sold 15,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 1st. The stock was sold at an average price of $74.82, for a total value of $1,122,300.00. Following the completion of the sale, the executive vice president now directly owns 77,363 shares in the company, valued at approximately $5,788,299.66. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider John F. Milligan sold 220,000 shares of the business’s stock in a transaction that occurred on Monday, November 13th. The shares were sold at an average price of $72.88, for a total value of $16,033,600.00. The disclosure for this sale can be found here. Insiders have sold a total of 461,666 shares of company stock worth $34,072,567 over the last 90 days. 1.30% of the stock is owned by company insiders.
Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.13 by $0.14. Gilead Sciences had a return on equity of 57.15% and a net margin of 42.22%. The company had revenue of $6.51 billion for the quarter, compared to the consensus estimate of $6.40 billion. During the same period in the previous year, the business earned $2.75 EPS. Gilead Sciences’s revenue for the quarter was down 13.2% compared to the same quarter last year. equities analysts anticipate that Gilead Sciences, Inc. will post 8.53 earnings per share for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which was paid on Thursday, December 28th. Shareholders of record on Friday, December 15th were issued a dividend of $0.52 per share. The ex-dividend date of this dividend was Thursday, December 14th. This represents a $2.08 annualized dividend and a yield of 2.79%. Gilead Sciences’s dividend payout ratio is presently 23.66%.
Several equities research analysts recently commented on the company. Credit Suisse Group set a $80.00 target price on Gilead Sciences and gave the company a “hold” rating in a report on Wednesday, January 3rd. BMO Capital Markets reiterated a “hold” rating on shares of Gilead Sciences in a report on Wednesday, January 3rd. Zacks Investment Research downgraded Gilead Sciences from a “hold” rating to a “sell” rating in a report on Wednesday, December 27th. Oppenheimer reiterated a “hold” rating on shares of Gilead Sciences in a report on Thursday, December 21st. Finally, BidaskClub upgraded Gilead Sciences from a “sell” rating to a “hold” rating in a report on Thursday, December 14th. One investment analyst has rated the stock with a sell rating, fourteen have given a hold rating, sixteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. Gilead Sciences currently has a consensus rating of “Buy” and a consensus target price of $85.03.
TRADEMARK VIOLATION WARNING: This piece of content was originally posted by Community Financial News and is owned by of Community Financial News. If you are reading this piece of content on another website, it was copied illegally and republished in violation of international copyright and trademark legislation. The original version of this piece of content can be accessed at https://www.com-unik.info/2018/01/08/gilead-sciences-inc-gild-shares-bought-by-sunbelt-securities-inc.html.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
What are top analysts saying about Gilead Sciences? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Gilead Sciences and related companies.